DPP4 and hydrops fetalis: The SAVOR trial reports a significantly higherincidence of HHF in patients treated with saxagliptin (3.5% vs. 2.8%; HR 1.27, 95%CI = 1.07–1.51)5, whichraised the issue of HF in relation to DPP4 inhibitors11, 12.